Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly
暂无分享,去创建一个
T. Shiraishi | K. Okihara | O. Ukimura | Kei Yamada | H. Yamazaki | Satoaki Nakamura | D. Shimizu | A. Fujihara | Koji Masui | Gen Suzuki | Norihiro Aibe | Ken Yoshida | Haruumi Okabe | H. Okabe
[1] M. Agudelo-Botero,et al. Epidemiology, progression, and predictive factors of urinary incontinence in older community‐dwelling Mexican adults: Longitudinal data from the Mexican Health and Aging Study , 2019, Neurourology and urodynamics.
[2] Y. Yoshioka,et al. Radiotherapy for Elderly Patients Aged ≥75 Years with Clinically Localized Prostate Cancer—Is There a Role of Brachytherapy? , 2018, Journal of clinical medicine.
[3] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[4] D. Dearnaley,et al. The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. , 2018, International journal of radiation oncology, biology, physics.
[5] L. Holmberg,et al. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] M. Aapro,et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. , 2017, European urology.
[7] H. Yamazaki,et al. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy. , 2017, Anticancer research.
[8] S. Kariya,et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. , 2017, Brachytherapy.
[9] P. Grosclaude,et al. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk , 2017, World Journal of Urology.
[10] David Gillatt,et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.
[11] S. K. Van Den Eeden,et al. Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[12] R. DiPaola,et al. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. , 2015, European urology.
[13] S. Naito,et al. Current use of active surveillance for localized prostate cancer: A nationwide survey in Japan , 2015, International journal of urology : official journal of the Japanese Urological Association.
[14] T. Miki,et al. Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate‐risk prostate cancer group without a Gleason score of 4 + 3: A single Japanese institutional experience , 2014, International journal of urology : official journal of the Japanese Urological Association.
[15] B. Davison,et al. Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. , 2012, Patient education and counseling.
[16] M. Gorin,et al. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. , 2011, Urology.
[17] Srinivasan Vijayakumar,et al. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. , 2005, Urology.
[18] J. Stanford,et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.